Wholesale tab tirzepatide

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Research Article Therapeutics Open Access | 10.1172/jci.insight.140532

Authors

Francis S. Willard,1 Jonathan D. Douros,2 Maria B.N. Gabe,3 Aaron D. Showalter,4 David B. Wainscott,1 Todd M. Suter,4 Megan E. Capozzi,2 Wijnand J.C. van der Velden,3 Cynthia Stutsman,4 Guemalli R. Cardona,1 Shweta Urva,5 Paul J. Emmerson,4 Jens J. Holst,3 David A. D’Alessio,2 Matthew P. Coghlan,4 Mette M. Rosenkilde,3 Jonathan E. Campbell,2 and Kyle W. Sloop 4

Affiliations

• 1 Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
• 2 Duke Molecular Physiology Institute, Duke University, Durham, North Carolina, USA.
• 3 Department of Biomedical Sciences and NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
• 4 Diabetes and Complications, and
• 5 PK/PD & Pharmacometrics, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.

Correspondence

Address correspondence to: Kyle W. Sloop, Lilly Corporate Center Drop Code 0520, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. Phone: 317.651.2856; Email: admin@frankenthalerfoundation.org.